このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Astec LifeSciences 将来の成長

Future 基準チェック /56

Astec LifeSciencesは、106.2%と30.9%でそれぞれ年率106.2%で利益と収益が成長すると予測される一方、EPSはgrowで106.2%年率。

主要情報

106.2%

収益成長率

106.2%

EPS成長率

Chemicals 収益成長	19.0%
収益成長率	30.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	09 Apr 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BSE:533138 - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2026	8,716	931	N/A	1,561	1
3/31/2025	6,756	579	N/A	813	1
3/31/2024	4,582	-469	-1,253	102	N/A
12/31/2023	4,317	-509	N/A	N/A	N/A
9/30/2023	4,981	-258	-1,580	101	N/A
6/30/2023	5,871	60	N/A	N/A	N/A
3/31/2023	6,285	256	-426	747	N/A
12/31/2022	7,735	736	N/A	N/A	N/A
9/30/2022	8,297	975	-448	351	N/A
6/30/2022	7,325	883	N/A	N/A	N/A
3/31/2022	6,769	899	-804	236	N/A
12/31/2021	5,803	708	N/A	N/A	N/A
9/30/2021	5,230	531	-800	483	N/A
6/30/2021	5,754	619	N/A	N/A	N/A
3/31/2021	5,587	650	-1,107	-82	N/A
12/31/2020	5,698	723	N/A	N/A	N/A
9/30/2020	5,786	774	1,190	1,885	N/A
6/30/2020	5,639	648	N/A	N/A	N/A
3/31/2020	5,287	475	1,231	1,684	N/A
12/31/2019	4,844	291	N/A	N/A	N/A
9/30/2019	4,781	269	-420	32	N/A
6/30/2019	4,507	331	N/A	N/A	N/A
3/31/2019	4,382	357	-375	153	N/A
12/31/2018	4,246	402	N/A	N/A	N/A
9/30/2018	3,781	374	N/A	N/A	N/A
6/30/2018	3,611	325	N/A	N/A	N/A
3/31/2018	3,676	349	150	647	N/A
12/31/2017	3,254	212	N/A	N/A	N/A
9/30/2017	3,119	148	N/A	N/A	N/A
6/30/2017	3,008	192	N/A	N/A	N/A
3/31/2017	2,987	191	N/A	192	N/A
12/31/2016	3,167	-29	N/A	N/A	N/A
9/30/2016	2,865	-114	N/A	N/A	N/A
6/30/2016	2,643	-206	N/A	N/A	N/A
3/31/2016	2,330	50	N/A	-125	N/A
12/31/2015	2,629	-115	N/A	N/A	N/A
9/30/2015	2,777	61	N/A	N/A	N/A
6/30/2015	2,728	84	N/A	N/A	N/A
3/31/2015	2,669	148	N/A	75	N/A
12/31/2014	2,212	131	N/A	N/A	N/A
9/30/2014	2,147	127	N/A	N/A	N/A
6/30/2014	2,156	96	N/A	N/A	N/A
3/31/2014	2,070	87	N/A	146	N/A
12/31/2013	2,179	97	N/A	N/A	N/A
9/30/2013	2,076	76	N/A	N/A	N/A
6/30/2013	1,849	72	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 533138は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 6.7% ) よりも高い成長率であると考えられます。

収益対市場: 533138今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 533138今後 3 年以内に収益を上げることが予想されます。

収益対市場: 533138の収益 ( 30.9% ) Indian市場 ( 9.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 533138の収益 ( 30.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 533138の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Astec LifeSciences 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target decreased by 14% to ₹1,108

Price target decreased by 9.3% to ₹1,205

Price target decreased to ₹1,923

Price target increased to ₹2,132

Price target increased to ₹1,869

Price target increased to ₹1,508

Recent updates

Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astec LifeSciences Limited to Report Q4, 2024 Results on May 02, 2024

Price target decreased by 14% to ₹1,108

Price target decreased by 9.3% to ₹1,205

Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023)

Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024

Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023)

Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023

Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023

Upcoming dividend of ₹1.50 per share at 0.1% yield

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Non-Executive Non-Independent Director recently sold ₹4.8m worth of stock

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Investor sentiment improves as stock rises 26%

Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022)

Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023

Price target decreased to ₹1,923

High number of new directors

Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022)

Astec Lifesciences Limited Announces Appointment of Mr. Madhur Gundecha as the Chief Financial Officer

Astec LifeSciences Limited to Report Q2, 2023 Results on Oct 28, 2022

Investor sentiment improved over the past week

Astec LifeSciences Limited Announces the Resignation of Saurav Bhala as Chief Financial Officer

Price target increased to ₹2,132

High number of new directors

Astec Lifesciences Limited Appoints Burjis Godrej as an Additional, Non-Executive, Non- Independent Director

Astec LifeSciences Limited to Report Q1, 2023 Results on Jul 25, 2022

Upcoming dividend of ₹1.50 per share

Full year 2022 earnings: Revenues exceed analyst expectations

Price target increased to ₹1,869

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

MD & Director recently bought ₹37m worth of stock

Astec LifeSciences Limited Announces Cessation of Ashok Hiremath as the Managing Director of the Company

Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock

Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock

Non-Executive Non-Independent Director recently bought ₹3.5m worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹1.5m worth of stock

Investor sentiment improved over the past week

Insider recently sold ₹2.4m worth of stock

Price target increased to ₹1,508

Price target increased to ₹1,386

Upcoming dividend of ₹1.50 per share

Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020)

Whole Time Director recently sold ₹2.9m worth of stock

Investor sentiment improved over the past week

MD & Director recently sold ₹240m worth of stock

Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020)

Astec Lifesciences Limited Recommends Final Dividend for the Year Ended March 31, 2021, Payable on August 6, 2021

Price target decreased to ₹1,221

Astec LifeSciences Limited to Report Q3, 2021 Results on Jan 25, 2021

New 90-day high: ₹1,194

MD & Director recently sold ₹440m worth of stock

New 90-day low: ₹986

MD & Director recently sold ₹527m worth of stock

First half earnings released

MD & Director recently sold ₹57m worth of stock

MD & Director recently sold ₹15.2m worth of stock

New 90-day high: ₹1,271

MD & Director recently sold ₹11.3m worth of stock

New 90-day high - ₹1,254

MD & Director recently sold ₹32.9m worth of stock

Astec LifeSciences Limited to Report Q1, 2021 Results on Jul 22, 2020